skip to main content

Prostate Cancer

How precision medicine is improving prostate cancer detection

New, statistically derived guidelines are helping urologists across Michigan zero in on which prostate cancer patients to scan for spread of their disease.

A new approach to target an 'undruggable' prostate cancer driver

When small-molecule inhibitors proved elusive, researchers developed a novel strategy: Using large molecule peptides to target a common prostate cancer driver. It may provide a path for developing new therapies against a challenging target.

Michigan Medicine opens first prostate cancer risk clinic in the nation

It’s well known that women with certain hereditary genetic mutations, particularly BRCA1 and BRCA2, have an increased risk of breast cancer. But in recent years, researchers have discovered a link between some of those same genetic mutations – along with a handful of others – and aggressive prostate cancer.

Prostate cancer treatment rates drop, reflecting change in screening recommendations

As some national guidelines now recommend against routine prostate cancer screening, the overall rate of men receiving treatment for the disease declined 42 percent, a new study finds.

The PSA and beyond: An update on prostate cancer biomarkers

There is perhaps no hotter topic in prostate cancer treatment today than the use of prostate cancer biomarkers. To learn more about them, we posed a few questions to Todd Morgan, M.D., a surgeon in the U-M Multidisciplinary Urologic Oncology Clinic.

Pages